What are the risks of taking the shingles vaccine

The shingles vaccine (Shingrix) causes frequent, intense short-term reactions and carries a small but real risk of serious autoimmune and neurological events, while the live vaccine (Zostavax) is less effective and carries a different risk profile.

The evidence on Shingrix is dominated by manufacturer-funded trials. In the pivotal ZOE-50/70 trials, funded by GlaxoSmithKline, about 4 in 5 people reported injection-site reactions and about 1 in 6 reported systemic events like fever and chills, typically lasting 1-3 days [3][6]. A real-world Italian study of 675 vulnerable patients found 44 in 100 had an adverse event after either dose, with 4 in 100 reporting neurological symptoms [2]. The most important serious signal is Guillain-Barré syndrome: a self-controlled case series in people 65+ found about 3 excess GBS cases per million Shingrix doses within 42 days [5]. A VAERS analysis of 69,822 reports found GBS listed in 0.28% of reports, though this is a raw count without a denominator [1].

For people with autoimmune conditions, the risk is higher. A VAERS study found that among 920 patients with rheumatoid arthritis, lupus, or similar diseases, about 8 in 100 reported a disease flare after Shingrix, with lupus patients at the highest relative risk [7]. Most flares happened within 3 days of vaccination [7]. The live Zostavax vaccine carries a different risk: about 28 in 100 VAERS reports for it were classified as serious, largely driven by reports of shingles and rash after the live virus [1]. In immunocompromised people, live vaccine can cause severe or fatal disseminated infection [4].

The evidence base has critical gaps. No long-term safety study comparing vaccinated to genuinely unvaccinated people was found in this retrieval. The safety data relies heavily on passive VAERS reporting, which captures only a fraction of real events. The manufacturer funded nearly every major trial, and the adjuvant system (AS01B) is a potent immune stimulant whose long-term effects on immune regulation are not fully characterized.

My call: the shingles vaccine trades a high rate of short-term misery and a small but real risk of serious harm for a roughly 85-90% reduction in shingles risk over about 8 years. For a healthy 50-year-old, the benefit may not justify the reaction burden. For an older or immunocompromised person at higher shingles risk, the trade-off shifts. The evidence is not clear enough to call it a clear win for anyone. Confidence: moderate.